Search clinical trials for: 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)

Total 68 results

Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

Australia
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Kidney Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
University of Nebraska
National Cancer Institute (NCI); Coulter Pharmaceutical, Inc.

Terminated

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Sarcoma | Lung Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Duke University

Completed

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

Brain and Central Nervous System Tumors

United States
Duke University

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Brain and Central Nervous System Tumors | Metastatic Cancer

United States
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Peregrine Pharmaceuticals

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Brain and Central Nervous System Tumors

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Colorectal Cancer

United States, Australia
Duke University
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

Brain and Central Nervous System Tumors

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer

United States
Corixa Corporation

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Non-Hodgkin's Lymphoma

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Non-Hodgkin's Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Completed

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Lymphoma, Non-Hodgkin
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United Kingdom, United States
Memorial Sloan Kettering Cancer Center
Ludwig Institute for Cancer Research

Active, not recruiting

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumor | COlorectal Carcinoma

United States
GlaxoSmithKline

Completed

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
Centre René Gauducheau

Completed

Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131 (BB4)

Multiple Myeloma

France
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Garden State Cancer Center at the Center for Molecular...

Unknown

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

Colorectal Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
New Approaches to Neuroblastoma Therapy Consortium
United Therapeutics

Active, not recruiting

MIBG With Dinutuximab +/- Vorinostat

Neuroblastoma

United States
Darell D. Bigner, MD, PhD
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Brain and Central Nervous System Tumors | Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
University of Nebraska

Completed

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Brain and Central Nervous System Tumors

United States
Bradmer Pharmaceuticals Inc.

Unknown

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Brain Tumors

United States
West China Hospital

Not yet recruiting

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States

Search clinical trials for: 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations